NCT00720629 · OUTCOME

Overall Survival (OS)

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation · Source last updated 2014-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Median OS in days. Survival was measured from the time of transplant to the time of death.

Analysis population: Participants who had died by Year 2 and additional participants who had died by Year 5.

First Study Stage: Study Treatment. Visilizumab, Tacrolimus and Methotrexate.

First Study Stage: Study Treatment. Visilizumab, Tacrolimus and Methotrexate.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
2 Year Analysis Group	6
5 Year Analysis Group	2

Source class 1

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
2 Year Analysis Group	197	Not reported	150	643	Not reported
5 Year Analysis Group	1803	Not reported	1791	1816	Not reported

Complete source fields

classes

denoms

description

Median OS in days. Survival was measured from the time of transplant to the time of death.

dispersion Type

Full Range

groups

param Type

MEDIAN

population Description

Participants who had died by Year 2 and additional participants who had died by Year 5.

reporting Status

POSTED

time Frame

At 2 years and 5 years

title

Overall Survival (OS)

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice